

ORLICA 60

For the use of a Registered Medical Practitioner or a Hospital or Laboratory only

Abbreviated Prescribing information for Orlica 60 (Orlistat Capsules)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats.

INDICATION: Orlistat is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Orlistat is also indicated to reduce the risk for weight regain after prior weight loss. Orlistat is indicated for obese patients with an initial body mass index (BMI) ≥ 30 kg/m² or ≥ 27 kg/m² in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).

DOSAGE AND ADMINISTRATION: The dosage of orlistat for the management of obesity and weight regain in adults is 120 mg 3 times daily with each main meal containing fat.

CONTRINDICATIONS: patients with chronic malabsorption syndrome or cholestasis, and in patients with known hypersensitivity to orlistat or to any component of this product.

WARNINGS & PRECAUTIONS: Organic causes of obesity (e.g., hypothyroidism) should be excluded before prescribing orlistat. orlistat and cyclosporine should not be coadministered. To reduce the chance of a drug-drug interaction, cyclosporine should be taken at least 2 hours before or after orlistat in patients taking both drugs. Gastrointestinal events may increase when orlistat is taken with a diet high in fat (>30% total daily calories from fat).

ADVERSE REACTIONS: Oily spotting, flatulence with discharge, fecal urgency, oily evacuation, increased defecation, fecal incontinence, oily rectal leakage, upper respiratory infection, steatorrhea, gingival disorders, nausea, rectal irritation and tooth disorder.

MARKETED BY:

TORRENT
PHARMA

TORRENT PHARMACEUTICALS LTD.

IN/ORLICA 60/MAR-2026/02/ABPI

(Additional information is available on request)